Cate Lockhart, executive director of the Biologics and Biosimilars Collective Intelligence Consortium, shared results yesterday of a survey that look at biosimilars on the pharmacy benefit side of coverage versus medical benefit. The survey also shared how payers and those on the pharmaceutical side are anticipating the introduction of Adalimumab (Humira®), as well as what to look for in the future of the biosimilar pipeline.
Data revealing the concerns and plans of payers and formulary managers was the highlighted topic of discussion during a session yesterday co-presented by Cate Lockhart, executive director of the Biologics and Biosimilars Collective Intelligence Consortium.
Conducted in a survey, the data shared the anticipation of Adalimumab (Humira®) and looked at biosimilars on a pharmacy benefit side of coverage versus medical benefit. These results were presented by Lockhart and others at the Asembia 2023 Specialty Pharmacy Summit in Las Vegas.
Expressing the future of the biosimilars pipeline is "quite rich," Lockhart said payers have been pretty comfortable with them and are actively looking at ways to incorporate them.
Though, there are some questions concering biosimilars when it comes to operationalizing coverage.
To take a deeper dive into Lockhart's discussion, watch our interview above.